These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 33776461)

  • 21. Effects of Dapagliflozin Compared with Sitagliptin and Metformin in Drug-Naïve Japanese Patients with Type 2 Diabetes: A 12-Week, Open-Label, Randomized, Active-Controlled Trial.
    Ito D; Inoue K; Saito D; Hamaguchi K; Kaneko K; Sumita T; Inukai K; Inoue I; Shimada A
    Diabetes Ther; 2021 Dec; 12(12):3201-3215. PubMed ID: 34709582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial.
    Peng XV; Marcinak JF; Raanan MG; Cao C
    Diabetes Obes Metab; 2017 Aug; 19(8):1127-1134. PubMed ID: 28239939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of sitagliptin compared with sulfonylurea therapy in patients with type 2 diabetes showing inadequately controlled glycosylated hemoglobin with metformin monotherapy: A meta-analysis.
    Hou L; Zhao T; Liu Y; Zhang Y
    Exp Ther Med; 2015 Apr; 9(4):1528-1536. PubMed ID: 25780464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Pioglitazone/Metformin Fixed-Dose Combination Versus Uptitrated Metformin in Patients with Type 2 Diabetes without Adequate Glycemic Control: A Randomized Clinical Trial.
    Guo LX; Wang LW; Tian DZ; Xu FM; Huang W; Wu XH; Zhu W; Chen JQ; Zheng X; Zhou HY; Li HM; He ZC; Wang WB; Ma LZ; Duan JT
    Diabetes Ther; 2024 Nov; 15(11):2351-2366. PubMed ID: 39283411
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes.
    Williams-Herman D; Engel SS; Round E; Johnson J; Golm GT; Guo H; Musser BJ; Davies MJ; Kaufman KD; Goldstein BJ
    BMC Endocr Disord; 2010 Apr; 10():7. PubMed ID: 20412573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
    Srivastava S; Saxena GN; Keshwani P; Gupta R
    J Assoc Physicians India; 2012 Mar; 60():27-30. PubMed ID: 22799111
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sitagliptin in type 2 diabetes mellitus: Efficacy after five years of therapy.
    Derosa G; D'Angelo A; Maffioli P
    Pharmacol Res; 2015 Oct; 100():127-34. PubMed ID: 26211947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metformin and sitAgliptin in patients with impAired glucose tolerance and a recent TIA or minor ischemic Stroke (MAAS): study protocol for a randomized controlled trial.
    Osei E; Fonville S; Zandbergen AA; Brouwers PJ; Mulder LJ; Lingsma HF; Dippel DW; Koudstaal PJ; den Hertog HM
    Trials; 2015 Aug; 16():332. PubMed ID: 26242578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.
    Meloni AR; DeYoung MB; Han J; Best JH; Grimm M
    Cardiovasc Diabetol; 2013 Mar; 12():48. PubMed ID: 23522121
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.
    Yang HK; Lee SH; Shin J; Choi YH; Ahn YB; Lee BW; Rhee EJ; Min KW; Yoon KH
    Diabetes Metab J; 2019 Jun; 43(3):287-301. PubMed ID: 30604599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.
    Schernthaner G; Matthews DR; Charbonnel B; Hanefeld M; Brunetti P;
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6068-76. PubMed ID: 15579760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
    Choy M; Lam S
    Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
    Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Oral Antidiabetic Drugs on Changes in the Liver-to-Spleen Ratio on Computed Tomography and Inflammatory Biomarkers in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
    Yabiku K; Mutoh A; Miyagi K; Takasu N
    Clin Ther; 2017 Mar; 39(3):558-566. PubMed ID: 28185715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Fixed Combination of Metformin and Pioglitazone on Insulin Resistance of Patients with Type 2 Diabetes: Results of a Randomized Open-Label Study.
    Sun R; Yuan L; Shen Y; Shen Z; Ding B; Ma J
    Diabetes Metab Syndr Obes; 2023; 16():2911-2919. PubMed ID: 37753480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Comparison of the Effects of Empagliflozin and Sitagliptin, When Combined With Metformin, on Lipid Levels in Patients with Type 2 Diabetes: A Clinical Investigation.
    Ahmed M; Saeed A; Khan MZ; Javaid SZ; Aslam F; Dar SI
    Cureus; 2023 Sep; 15(9):e44709. PubMed ID: 37809225
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Efficacy and Safety of the Chinese Herbal Formula, JTTZ, for the Treatment of Type 2 Diabetes with Obesity and Hyperlipidemia: A Multicenter Randomized, Positive-Controlled, Open-Label Clinical Trial.
    Yu X; Xu L; Zhou Q; Wu S; Tian J; Piao C; Guo H; Zhang J; Li L; Wu S; Guo M; Hong Y; Pu W; Zhao X; Liu Y; Pang B; Peng Z; Wang S; Lian F; Tong X
    Int J Endocrinol; 2018; 2018():9519231. PubMed ID: 29808092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of herbal medicine compound promotes beta cell function among type 2 diabetes (T2D) adults: A randomized controlled clinical trial.
    Zhang Z; Gao Q; Li S; Zeng Z; Zhang Y
    Contemp Clin Trials Commun; 2023 Oct; 35():101166. PubMed ID: 37520328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Effects of 6 Common Antidiabetic Drugs on Anti-PD1 Immune Checkpoint Inhibitor in Tumor Treatment.
    Zhan ZT; Liu L; Cheng MZ; Gao Y; Zhou WJ
    J Immunol Res; 2022; 2022():2651790. PubMed ID: 36033393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Two-Stage Study Identifies Two Novel Polymorphisms in
    Xiao D; Liu JY; Zhang SM; Liu RR; Yin JY; Han XY; Li X; Zhang W; Chen XP; Zhou HH; Ji LN; Liu ZQ
    Pharmgenomics Pers Med; 2021; 14():745-755. PubMed ID: 34188521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.